Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 460-490-0 | CAS number: 477218-42-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- An assessment of toxicokinetics, based on available data, in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006
- Type of information:
- other: Desk-based assessment
- Adequacy of study:
- key study
- Study period:
- Not applicable
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- An assessment of toxicokinetics, based on available data, in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006
- GLP compliance:
- no
- Details on species / strain selection:
- No animals were used in this desk-based assessment.
- Details on test animals or test system and environmental conditions:
- Not applicable
- Details on exposure:
- Desk-based assessment.
- Duration and frequency of treatment / exposure:
- Desk-based assessment.
- No. of animals per sex per dose / concentration:
- No animals were used in this desk-based assessment.
- Positive control reference chemical:
- Desk-based assessment.
- Details on study design:
- Not applicable
- Details on dosing and sampling:
- Not applicable
- Statistics:
- Not applicable
- Preliminary studies:
- Desk-based assessment.
- Details on absorption:
- The physicochemical properties of the substance i.e. molecular weight of 296.451 g/mol, vapor pressure of 1.5 Pa at 20 °C, Log Pow of 5.5 to 5.6 at 35 °C, along with water solubility of 3.85 mg/L at 20 °C are indicative of potential absorption by oral route with uptake via intracellular pathway. Intake from the intracellular and active transport (influx) pathway exits through the basolateral membrane into the portal blood which results in first pass metabolism in the liver, this means that the concentration of the parent substance is reduced before reaching systemic circulation. Evidence of oral absorption is demonstrated by the clinical and macroscopic abnormalities observed following sub-acute oral exposure. Although similar absorption pattern is expected via inhalation, the substance is not highly volatile (vapor pressure of 1.5 Pa at 20 °C and high boiling point of 331 °C), this means bioavailability via this route is more limited. This is supported by the low acute inhalation toxicity observed in rat. In the absence of specific absorption data via this route, the conservative default route-to-route extrapolation can be applied with pulmonary absorption set at 100% for risk assessment purpose. Based on the high Log Pow of 5.5 to 5.6, the molecular weight above 100 g/mol, the low surface activity (surface tension 49.9 mN/m) and low water solubility, indicates dermal absorption may be more limited since the rate of penetration can be limited by the rate of transfer between the stratum corneum and the epidermis. Nevertheless, based on the indicated sensitisation potential of the test item, it shows some systemic uptake must occur although it may only be a small fraction of the applied dose. It can be considered the overall uptake via this route is very low demonstrated by the lack of toxicity observed following exposure during in vivo dermal studies. As a Tier I screen, in the absence of absorption data via this route, the conservative default value of 100% adsorption is used for risk assessments.
- Details on distribution in tissues:
- Based on the physicochemical properties and the observation of systemic toxicity following sub-acute exposure, a wide distribution of substance and/or its metabolite is expected. This is supported by observed histopathological changes in the heart, skeletal muscle, kidneys, Harderian gland, liver, and thyroid following sub-acute oral exposure at specified higher dose levels. Reduced mean grip strength and sedation are a demonstration of potential distribution to central nervous system (CNS). As the log Pow value is > 4 a longer biological half-life is expected resulting in a build-up of substance following continuous exposure at high concentration. This would result in toxicity as demonstrated in some of the histopathological changes observed after the two weeks recovery within the specified higher dose levels of the OECD 407 (2004) study within rats. Distribution of the substance into/past the stratum corneum is also expected based on log Pow of 5.6 as noted by the sensitisation observed in guinea pig and mice studies. However, based on the physicochemical properties of the substance systemic distribution via dermal exposure is more limited. Additionally, accumulation is more limited to the stratum corneum, and it is considered can be eventually be cleared as the stratum corneum is sloughed off.
- Details on excretion:
- The substance Log Pow is in the range of 5.5 to 5.6. The water solubility of 3.85 mg/L and the molecular weight of < 500 are indicative of longer biological half-life resulting in a build-up of the substance in vivo following absorption via the GI tract. However, uptake of the substance through intracellular and active transport (influx) pathway(s) and subsequent exit through the basolateral membrane into the portal blood would result in first pass metabolism in the liver. The metabolites are expected to be more polar derivatives, excreted via urine. Based on the molecular structure and solubility, they would be excreted into bile and urine as conjugated metabolites. Glucuronide conjugates are extensively excreted via bile, whereas sulphate conjugates are excreted via urine. This is supported by observed increased kidney weights with high incidences hyaline droplets and tubular basophilia following sub-acute exposure via oral route.
- Metabolites identified:
- not measured
- Details on metabolites:
- Metabolism is primarily through reductive and oxidative Phase I enzyme-catalyzed reactions in the liver and the GI track as demonstrated by the observed hepatocyte vacuolation which is considered an adaptive response to a xenobiotic. The main metabolic enzymes are non-P450 aldehyde reduction enzyme systems alcohol dehydrogenase (ADH), aldo-keto reductase (AKR) and short-chain dehydrogenase/reductase (SDR), and aldehyde oxidation enzyme systems xanthine oxidase (XO), aldehyde oxidase (AOX), aldehyde dehydrogenase (ALDH), esterase and hydrolases. Based on the structure of the substance: the metabolic pathway (hydrolysis) involving esterases and hydrolases are the most common and will result into production of: alcohol, aldehyde, carboxylic acid and ketone metabolite derivatives. The alcohol, aldehyde and ketone derivatives will be metabolised mainly by ADH, ALDH and to a lesser extend AKR, OX and AOX enzyme systems; producing carboxylic acid derivative(s). The carboxylic acidic derivatives will be further conjugated with glucuronides and sulphate via glucuronsyl transferase and sulphotransferase with subsequent elimination via urine. At low dose exposure, sulphation is expected to dominate, but as the doses increase glucuronidation becomes the major route of metabolism as glucuronsyl transferase has higher capacity than sulphotransferase. Observed metabolic turnover of the substance by Rainbow trout liver S9 fractions in vitro and observed increased metabolic enzyme activities such as aspartate aminotransferase and lactate dehydrogenase in rat in vivo studies are indicative of substance biotransformation. Histopathological changes in the liver in the form of increased incidence and mean grades of liver fatty change and increased incidence and mean grades of hepatocellular (centrilobular) hypertrophy, were observed within OECD 407 and OECD 422 studies and which are further indication of metabolism.
- Conclusions:
- The substance possesses physicochemical properties which are favourable for ADME. The substance possesses physicochemical properties which are favourable for ADME. Available data demonstrate the potential for absorption as evidence by systemic toxicity under sub-acute oral exposure. The substance and its metabolites are widely distributed as demonstrated by observed effects in various organs including the Central Nervous System (CNS). Observations in liver and kidney demonstrate the biotransformation and elimination of the substance and its metabolites. There was no evidence of accumulation observed at the primary site of exposure (the gut) as demonstrated in the longer-term studies. In addition, the bioconcentration factor (BCF) within fish (corrected for mean lipid content 5%) was reported as 103 L/kg ww. The substance is not acutely toxic via all tested routes of exposure (oral, inhalation and dermal). Although no irritation is observed via local exposure, sensitisation was noted in vivo, this demonstrates potential protein binding, although the lack of observed systemic toxicity could be demonstration of reduced uptake from/through the stratum corneum. Specific target organ toxicities in the heart, lung, kidney and liver within sub-acute studies were reported. These consisted of minimal acinar degeneration, minimal to slight acinar hyperplasia, and increased porphyrin deposition in Harderian gland. In the heart, at higher administered dose levels: minimal to severe sarcoplasmic vacuolation, minimal to moderate single cell necrosis, increased incidence and mean grade of mononuclear foci, and minimal myocardial (interstitial) fibrosis were recorded in both sexes and multifocal progressive cardiomyopathy in observed females. In the kidney, increased incidence and mean grade of hyaline droplets and of tubular basophilia was recorded in the kidney of treated males; this was considered unrelated to treatment. Centrilobular hypertrophy was noted in the liver within 5/10 males and 5/10 females and haematopoiesis increased in females. Changes in the liver were considered an adaptive response since it was associated with hepatic enzyme induction i.e. increase aspartate aminotransferase activity (both sexes), elevated lactate dehydrogenase activity (females) and the elevated metabolite; ketone (both sexes). This toxicity is potentially driven by the log Pow which is within the range of 5.5 to 5.6 and the water solubility of 3.85 mg/L, which result in a longer biological half-life with potential accumulation of the substance following continuous exposure at high concentrations. However, the molecular weight is low with uptake via intracellular and active transport (influx) expected resulting in first pass metabolism with reduction in the concentration of the parent substance. Metabolism is influence by enzyme activity and continuous exposure especially at high concentration would result in enzymes saturation and reduced output. It is considered highly likely that this is the driving factor in the observed toxicity rather than tissue. It can be concluded that the bioaccumulation potential of the substance is low. However, it is noted that a prolonged half-life may result from metabolic output reduction which could result from enzyme saturation under continuous exposures at high concentrations.
- Executive summary:
A desk-based assessment of the basic toxicokinetics of the substance, in accordance with Regulation (EC) 1907/2006: Annex VIII - Section 8.8.1. The substance possesses physicochemical properties which are favourable for ADME. Available data demonstrate the potential for absorption as evidence by systemic toxicity under sub-acute oral exposure. The substance and its metabolites are widely distributed as demonstrated by observed effects in various organs including the Central Nervous System (CNS). Observations in liver and kidney demonstrate the biotransformation and elimination of the substance and its metabolites. There was no evidence of accumulation observed at the primary site of exposure (the gut) as demonstrated in the longer-term studies such as the OECD, 407 and OECD 421. In addition, the bioconcentration factor (BCF) within fish (corrected for mean lipid content 5%) was reported as 103 L/kg ww, which is significantly lower than the cut of value of 2000 for substances that would be considered bioaccumulative. The substance is not acutely toxic via all tested routes of exposure (oral, inhalation and dermal). Although no irritation is observed via local exposure, sensitisation was noted in vivo in both guinea pig and mice studies, this demonstrates potential protein binding, although the lack of observed systemic toxicity could be demonstration of reduced uptake from/through the stratum corneum. Specific target organ toxicities in the heart, lung, kidney and liver within sub-acute studies were reported. These consisted of minimal acinar degeneration, minimal to slight acinar hyperplasia, and increased porphyrin deposition in Harderian gland. In the heart, at higher administered dose levels: minimal to severe sarcoplasmic vacuolation, minimal to moderate single cell necrosis, increased incidence and mean grade of mononuclear foci, and minimal myocardial (interstitial) fibrosis were recorded in both sexes and multifocal progressive cardiomyopathy in observed females. In the kidney, increased incidence and mean grade of hyaline droplets and of tubular basophilia was recorded in the kidney of treated males; this was considered unrelated to treatment. Centrilobular hypertrophy was noted in the liver within 5/10 males and 5/10 females and haematopoiesis increased in females. Changes in the liver were considered an adaptive response since it was associated with hepatic enzyme induction i.e. increase aspartate aminotransferase activity (both sexes), elevated lactate dehydrogenase activity (females) and the elevated metabolite; ketone (both sexes). This toxicity is potentially driven by the substance n-Octanol/Water partition coefficient (log Pow) which is within the range of 5.5 to 5.6 and the water solubility of 3.85 mg/L, which result in a longer biological half-life with potential accumulation of the substance following continuous exposure at high concentrations. However, the molecular weight is low with uptake via intracellular and active transport (influx) expected resulting in first pass metabolism with reduction in the concentration of the parent substance. Metabolism is influence by enzyme activity and continuous exposure especially at high concentration would result in enzymes saturation and reduced output. It is considered highly likely that this is the driving factor in the observed toxicity rather than tissue bioaccumulation especially since a reversal was observed as demonstrated by recovery and/or reduction in specific histopathological changes observed during the two weeks recovery period under the OECD 407 study in rats.It can be concluded that the bioaccumulation potential of the substance is low. However, it is noted that a prolonged half-life may result from metabolic output reduction which could result from enzyme saturation under continuous exposures at high concentrations. This was supported by the observations of reversal/reduction of effects at low administered concentrations during the recovery phase of the OECD 407 study.
Reference
Description of key information
Toxicokinetics Assessment: no bioaccumulation potential; desk-based assessment in accordance with Regulation (EC) 1907/2006: Annex VIII, Section 8.8.1, 2020
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Basictoxicokinetics: expert assessment, 2020 : The substance possesses physicochemical properties which are favourable for ADME. Available data demonstrate the potential for absorption as evidence by systemic toxicity under sub-acute oral exposure. The substance and its metabolites are widely distributed as demonstrated by observed effects in various organs including the Central Nervous System (CNS). Observations in liver and kidney demonstrate the biotransformation and elimination of the substance and its metabolites. There was no evidence of accumulation observed at the primary site of exposure (the gut) as demonstrated in the longer-term studies such as the OECD, 407 and OECD 421. In addition, the bioconcentration factor (BCF) within fish (corrected for mean lipid content 5%) was reported as 103 L/kg ww, which is significantly lower than the cut of value of 2000 for substances that would be considered bioaccumulative. The substance is not acutely toxic via all tested routes of exposure (oral, inhalation and dermal). Although no irritation is observed via local exposure, sensitisation was noted in vivo in both guinea pig and mice studies, this demonstrates potential protein binding, although the lack of observed systemic toxicity could be demonstration of reduced uptake from/through the stratum corneum. Specific target organ toxicities in the heart, lung, kidney and liver within sub-acute studies were reported. These consisted of minimal acinar degeneration, minimal to slight acinar hyperplasia, and increased porphyrin deposition in Harderian gland. In the heart, at higher administered dose levels: minimal to severe sarcoplasmic vacuolation, minimal to moderate single cell necrosis, increased incidence and mean grade of mononuclear foci, and minimal myocardial (interstitial) fibrosis were recorded in both sexes and multifocal progressive cardiomyopathy in observed females. In the kidney, increased incidence and mean grade of hyaline droplets and of tubular basophilia was recorded in the kidney of treated males; this was considered unrelated to treatment. Centrilobular hypertrophy was noted in the liver within 5/10 males and 5/10 females and haematopoiesis increased in females. Changes in the liver were considered an adaptive response since it was associated with hepatic enzyme induction i.e. increase aspartate aminotransferase activity (both sexes), elevated lactate dehydrogenase activity (females) and the elevated metabolite; ketone (both sexes). This toxicity is potentially driven by the substance n-Octanol/Water partition coefficient (log Pow) which is within the range of 5.5 to 5.6 and the water solubility of 3.85 mg/L, which result in a longer biological half-life with potential accumulation of the substance following continuous exposure at high concentrations. However, the molecular weight is low with uptake via intracellular and active transport (influx) expected resulting in first pass metabolism with reduction in the concentration of the parent substance. Metabolism is influence by enzyme activity and continuous exposure especially at high concentration would result in enzymes saturation and reduced output. It is considered highly likely that this is the driving factor in the observed toxicity rather than tissue bioaccumulation especially since a reversal was observed as demonstrated by recovery and/or reduction in specific histopathological changes observed during the two weeks recovery period under the OECD 407 study in rats.It can be concluded that the bioaccumulation potential of the substance is low. However, it is noted that a prolonged half-life may result from metabolic output reduction which could result from enzyme saturation under continuous exposures at high concentrations. This was supported by the observations of reversal/reduction of effects at low administered concentrations during the recovery phase of the OECD 407 study.
References:
1. ECHA Guidance on Information Requirements and Chemical Safety Assessment (Chapter R.7c: Endpoint Specific Guidance, June 2017)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.